WASHINGTON -- Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), ...

ADT reduces testosterone, crucial for prostate cancer cell growth, but causes side effects impacting quality of life. Cardiovascular risks, insulin resistance, and bone density loss are significant ...

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

Men treated for prostate cancer after surgery now have clearer evidence that extending hormone therapy from six months to two ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond 9 to 12 months of ADT. HealthDay News — Increasing duration of androgen deprivation therapy (ADT) ...

A partitioned-survival lifetime model (2025 USD) compared ADT alone with seven intensification strategies across PFS, post-progression, and death, using published survival curves and literature-based ...

This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...

Patients who received ADT for 3 months or 9 months had worse overall survival than those treated for 36 months. For men with prostate cancer treated with definitive radiotherapy, the benefit derived ...